Interleukin-21 Gene Transfection Into Mouse Bladder Cancer Cells Results in Tumor Rejection Through the Cytotoxic T Lymphocyte Response

Journal of Urology

Volumn 176, Issue 3, 2006, Pages 1198-1203

  Furukawa, Junya ^b   Hara, Isao ^b   Nagai, Hiroshi ^a   Yao, Akihisa ^b   Oniki, Shuntaro ^a   Fujisawa, Masato ^b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

bladder; bladder neoplasms; gene therapy; interleukin 21; mice

Indexed keywords

CANCER ANTIBODY; CANCER VACCINE; INTERLEUKIN 21; LIPOFECTAMINE; MITOMYCIN C; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GK1 5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; CANCER CELL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL BASED GENE THERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME IMMUNOASSAY; EXPRESSION VECTOR; FEMALE; GENETIC ENGINEERING; GENETIC TRANSFECTION; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOLECULAR CLONING; MOUSE; MOUSE STRAIN; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUICIDE GENE THERAPY; SUPERNATANT; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR REJECTION;

ANIMALS; INTERLEUKINS; MICE; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 33746479282     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.04.037     Document Type: Article

References (17)

1. Bamias A., Tiliakos I., Karali M.D., and Dimopoulos M.A. Systemic chemotherapy in inoperable or metastatic bladder cancer. Ann Oncol (2005)
2. Bamias A., Moulopoulos L.A., Koutras A., Aravantinos G., Fountzilas G., Pectasides D., et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. Cancer 106 (2006) 297
3. Watanabe E., Matsuyama H., Matsuda K., Ohmi C., Tei Y., Yoshihiro S., et al. Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guerin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother 52 (2003) 481
4. Ludwig A.T., Moore J.M., Luo Y., Chen X., Saltsgaver N.A., O'Donnell M.A., et al. Tumor necrosis factor-related apoptosis-inducing ligand. a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res 64 (2004) 3386
5. Hara I., Hotta H., Sato N., Eto H., Arakawa S., and Kamidono S. Rejection of mouse renal cell carcinoma elicited by local secretion of interleukin-2. Jpn J Cancer Res 87 (1996) 724
6. Yamanaka K., Hara I., Nagai H., Miyake H., Gohji K., Micallef M.J., et al. Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model. Cancer Immunol Immunother 48 (1999) 297
7. Hara I., Nagai H., Miyake H., Yamanaka K., Hara S., Micallef M.J., et al. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration. Cancer Gene Ther 7 (2000) 83
8. Hara S., Nagai H., Miyake H., Yamanaka K., Arakawa S., Ichihashi M., et al. Secreted type of modified interleukin-18 gene transduced into mouse renal cell carcinoma cells induces systemic tumor immunity. J Urol 165 (2001) 2039
9. Hikosaka S., Hara I., Miyake H., Hara S., and Kamidono S. Antitumor effect of simultaneous transfer of interleukin-12 and interleukin-18 genes and its mechanism in a mouse bladder cancer model. Int J Urol 11 (2004) 647
10. Colombo M.P., and Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy. where are we now?. Immunol Today 15 (1994) 48
11. Colombo M.P., and Forni G. Immunotherapy. I: Cytokine gene transfer strategies. Cancer Metastasis Rev 16 (1997) 421
12. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408 (2000) 57
13. Parrish-Novak J., Foster D.C., Holly R.D., and Clegg C.H. Interleukin-21 and the IL-21 receptor. novel effectors of NK and T cell responses. J Leukoc Biol 72 (2002) 856
14. Kasaian M.T., Whitters M.J., Carter L.L., Lowe L.D., Jussif J.M., Deng B., et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation. a mediator of the transition from innate to adaptive immunity. Immunity 16 (2002) 559
15. Ugai S., Shimozato O., Kawamura K., Wang Y.Q., Yamaguchi T., Saisho H., et al. Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts. Cancer Gene Ther 10 (2003) 187
16. Ma H.L., Whitters M.J., Konz R.F., Senices M., Young D.A., Grusby M.J., et al. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-γ. J Immunol 171 (2003) 608
17. Di Carlo E., Comes A., Orengo A.M., Rosso O., Meazza R., Musiani P., et al. IL-21 induces tumor rejection by specific CTL and IFN-γ-dependent CXC chemokines in syngeneic mice. J Immunol 172 (2004) 1540